Commissioning post show updated | Seite 19

16649 Commissioning Newspaper-A4_Layout 1 04/08/2015 15:46 Page 19 www.healthpluscare.com “HEART UK supports GPs and clinical commissioning groups throughout England to establish programmes to improve diagnosis and management of FH” Jules Payne, Chief Executive HEART UK Familial hypercholesterolaemia (FH) is an inherited lipid disorder that confers a risk of premature coronary heart disease (CHD) because of lifelong exposure to high concentrations of low-density lipoprotein cholesterol (LDL-C). FH is a readily preventable cause of CHD, and treatment with lipid-lowering therapies reduces LDL-C concentrations and improves CHD outcome and survival. Only around 15,000 people are diagnosed FH in the UK, leaving more than 100,000 people undiagnosed, untreated and at risk of early cardiovascular disease. This substantial under-diagnosis represents a major gap in CHD prevention in the UK, especially when it is proven that exposure to lower LDL-C early in life is associated with a large reduction in CHD. In 2014, HEART UK published ‘Systematically Identifying Familial Hypercholesterolaemia in Primary Care: An Audit within the Medway Clinical Commissioning Group’, which described one CCGs approach to improving diagnosis of FH. The Medway study was conducted in two stages, first an FH Audit Tool was implemented in GP practices and secondly a FH Nurse Advisor Programme was established. This systematic approach identified new index cases of FH from data already available within GP systems and these two simple interventions doubled the number of FH patients diagnosed in Medway CCG. “The Medway audit is a huge step forward and offers a model that could be implemented within other CCGs in England; to systematically identify people at risk of FH and offer them appropriate treatment.” Professor Huon Gray, National Clinical Director for Heart Disease The Medway FH Audit Tool is compatible with most GP electronic record systems and is loaded remotely, requiring no additional work for the practices or clinicians. At a practice level individual patient data can be reviewed, audits can be conducted daily, if necessary and audit list generated. At a CCG level the software enables GP commissioners to extract and analyse near real-time data from GP systems without adding extra burden on GP practices. The Medway FH Audit Tool identifies all patients already with an FH diagnosis and identifies a group of people with elevated total cholesterol and/or LDL-C potentially at risk of FH. Electronic flags are added to these records prompting assessment when the patient next visited the practice. Training materials will be provided by HEART UK to participating CCGs. A resources pack for primary care is available from HEART UK, supporting practices to diagnosed and manage FH. patients diagnosed with FH and ‘at risk and unscreened’, after which the FH Audit Tool triggers and prompts to diagnose and manage FH will be activated. Measuring outcome. Measurements of the number of FH diagnosed and changes in lipid levels will be assessed at the CCG level at three months intervals for 12 months. As part of any project CCGs would agree to provide audit information to HEART UK and support the publication of the study results in an annual report and in peer-reviewed publications. For an informal discussion about Medway study and The Medway FH Audit Tool call Simon Williams at HEART UK on 01628 777046 A Seminar at project launch, arranged by HEART UK for participating GP practices to discuss the importance and benefits of diagnosing FH, the Medway model, audit participation, and impact on workload HEART UK- The Cholesterol Charity aims to prevent premature deaths caused by high cholesterol and cardiovascular disease. HEART UK works to raise awareness of the risks of high cholesterol, lobbies for better detection of those at risk, provides advice and information to patients and clinicians, and supports healthcare professional training. Establishing the baseline number of FH patients. Initially the FH Audit Tool will establish the baseline number of Sanofi provided supported for HEART UK’s stand and Q&A Session at the Commissioning Show. GENERAL PRACTICE NEEDS TO SCALE UP AND PROVIDE A MULTI-PROFESSIONAL SERVICE Getting the skill mix right and good leadership are key for )ѡ